Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease.
| Autor: | Pampín-Sánchez R; Servicio de Farmacia, Hospital Universitario de Cabueñes, Gijón, Spain. Electronic address: pampin_3@hotmail.com., Martínez-Mugica-Barbosa C; Servicio de Farmacia, Hospital Universitario de Cabueñes, Gijón, Spain., Fonseca-Aizpuru EM; Servicio de Medicia Interna, Hospital Universitario de Cabueñes, Gijón, Spain., Barbazán-Vázquez FJ; Servicio de Farmacia, Hospital Universitario de Cabueñes, Gijón, Spain., Fernández-González B; Servicio de Farmacia, Hospital Universitario de Cabueñes, Gijón, Spain., Buznego-Súárez L; Servicio de Oftalmología, Hospital Universitario de Cabueñes, Gijón, Spain. |
|---|---|
| Jazyk: | English; Spanish; Castilian |
| Zdroj: | Medicina clinica [Med Clin (Barc)] 2023 Feb 10; Vol. 160 (3), pp. 113-117. Date of Electronic Publication: 2022 Sep 08. |
| DOI: | 10.1016/j.medcli.2022.05.007 |
| Abstrakt: | Introduction: Thyroid eye disease (TED) is a complex and incompletely understood rare autoimmune disorder. Objectives: To analyze the experience and the outcomes obtained with the use of intravenous tocilizumab in the treatment of TED. Methods: A retrospective analysis of adult patients diagnosed with active TED resistant to intravenous corticosteroids treated in a tertiary hospital between May 2012 and May 2021. Results: Eleven patients were included with a mean age of 52±12 (range 35-67) years. Nine patients were female and two were male. Patients received a median of 5±3.2 doses. Twenty out of twenty-four eyes achieved inactivation of TED at week 16. Proptosis response was achieved in 6/8 patients and diplopia response in 3/8 patients. The GO-QOL questionnaire showed clinically significant improvement in 9/11 patients. No serious adverse effects were reported during tocilizumab treatment. One patient required decompressive surgery 15 months after tocilizumab therapy. Conclusion: The results obtained show that the use of tocilizumab in the treatment of this pathology can be a good alternative. (Copyright © 2022 Elsevier España, S.L.U. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|